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ABSTRACT 
Background: In the United States, human immunodeficiency virus (HIV) remains a substantial public health issue. There is 
evidence that the use of antiretroviral medications such as pre-exposure prophylaxis (PrEP) can be a safe and effective primary 
prevention strategy to reduce new cases of HIV infection. Provider practice behavior as it relates to prescribing PrEP and the 
potential impact on specific vulnerable populations needs increased attention. Few studies have evaluated the attitudes of 
physicians towards ethical issues related to prescribing PrEP. 
 
Methods: The purpose of the present literature review was to evaluate provider attitudes toward the ethics of prescribing PrEP for 
individuals at risk of acquiring HIV infection. Searches of the PubMed and Cochrane databases were conducted. Three reviewers 
independently assessed the relevance of articles and discarded those not directly related to the attitudes of physicians toward 
ethics of the cost, safety, and resource allocation of PrEP. A total of twenty-one articles were included in the review.  
 
Results: Provider attitudes and perceptions focused on three areas: resource allocation, cost, and safety or effectiveness of PrEP. 
Providers who were hesitant in prescribing PrEP were concerned with the availability of resources, patient adherence, risk of drug 
resistance, and toxicity. In the studies reviewed, few providers had prescribed PrEP; however, prescribing practices trended 
upward with time and awareness.  
 
Conclusions: Realization of the benefits of PrEP will require a utilitarian ethical approach to identifying the populations that will 
benefit most, monitoring for adverse effects, addressing costs, and educating and training providers to prescribe PrEP responsibly. 
Ensuring that PrEP fulfills its potential as part of a combination regimen for HIV prevention requires identification of additional 
evidence, education, support services, and resources that are needed, as well as the regulatory framework and cost scenarios for 
access to PrEP.  
 






In the United States and around the world, the human 
immunodeficiency virus (HIV) remains a substantial public 
health issue. In the United States, there are an estimated 1.2 
million people living with HIV (Centers for Disease Control 
[CDC], 2016a). In 2015, there were 39,513 new diagnoses 
of HIV (CDC, 2016a). Over recent years, there have been 
decreases in HIV incidence; however, these decreases are 
not consistent among all groups. The populations most 
affected by HIV are gay and bisexual men, who account for 
82% of new diagnoses among males (CDC, 2016a). 
Heterosexuals and injecting drug users also continue to be 
included in new HIV diagnoses, and African Americans 
continue to experience the greatest burden of HIV compared 
to other races (CDC, 2016a).  
 
There is evidence that the use of antiretroviral medications 
can be a safe and effective way to prevent HIV infection 
(Sugarman et al., 2014). Pre-exposure prophylaxis (PrEP) is 
a method for individuals who are at high risk of acquiring 
HIV infection to take a daily antiretroviral medication to 
decrease their risk of infection. The medication consists of 
two medicines, tenofovir and emtricitabine, in one pill. In 
July 2012, this medication (brand name Truvada) was 
approved by the Food and Drug Administration (FDA) for 
use as PrEP in HIV-uninfected individuals who are at a high 
risk of acquiring HIV infection (U.S. Food & Drug 
Administration, 2012). PrEP is taken daily in order to build 
up and maintain an effective concentration of the 
medication in the blood system to be protective against the 
HIV virus. The medication reduces the risk of the virus 
binding to CD4 cells and replicating (U.S. Food & Drug 
Administration, 2012). Although PrEP helps to prevent a 
high-risk individual from acquiring HIV, condoms should 
continue to be used as an additional barrier to other sexually 
transmitted infections (CDC, 2016b). According to the 
CDC, daily use of PrEP can reduce the risk of acquiring 
HIV from sexual intercourse by up to 90%, and, for 
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individuals who inject drugs, it can reduce the risk by up to 
70% (CDC, 2016b).  
 
PrEP and Ethical Decision-Making 
Contemporary public health strategies to prevent disease 
and promote wellness can be analyzed through the lens of 
established ethical models for decision making. One of these 
models, utilitarianism, was developed in the 19th century by 
Jeremy Bentham and John Stuart Mill to determine which 
laws were morally best for legislators to provide the greatest 
balance of good over evil (Velasquez et al., 2015). 
Utilitarianism has become a widely used ethical approach to 
decision making. These decisions are most commonly those 
that affect a large group of people, where the action in 
question provides the most good and does the least amount 
of harm. The HIV epidemic and the advent of PrEP provide 
an instructive example of the complexities of human health 
behaviors and utilitarian ethical decision-making in public 
health. 
 
 Understanding physicians’ attitudes toward the ethical 
considerations of prescribing PrEP is an essential 
component in increasing our awareness and understanding 
of practice patterns impacting population-level 
administration of PrEP. Primary care providers (PCPs) 
accomplish the first step in prescribing PrEP to the 
populations most at risk for acquiring HIV, for physicians 
must first identify appropriate courses of action. Then, often 
using utilitarian ethics, they consider the pros and the cons 
that are the results of the actions and choose the action that 
will provide the greatest benefit (Velasquez et al., 2015).  
 
The attitudes of physicians towards the cost, safety, and 
resource allocation aspects of PrEP can either hinder or 
promote its use. The medications cost an estimated $12,000 
per person per year; however, mathematical modeling 
suggests that, over time, PrEP programs have the potential 
to save costs for the healthcare system, showing a positive 
return on investment (Cappelletti, 2016). Under certain 
conditions, it is ethical to provide PrEP even when the 
supply of antiretrovirals available for treatment is low, 
because maximizing of the overall health benefits means 
giving priority to those who will respond best to treatment 
and survive the longest (Rennie, 2013; Macklin et al., 
2012). In regards to safety, although some studies have 
shown that PrEP is effective at reducing the incidence of 
new HIV infections, it could take years to compile sufficient 
evidence of the clinical safety and efficacy of PrEP for 
various populations. These cost and safety considerations 
can influence decisions on resource allocation. According to 
Hankins, Macklin, & Warren (2015), cost-effectiveness 
studies guide resource allocation decisions by indicating 
where resources can be applied for greatest impact. Hankins 
et al. (2015) argue that the outcomes-oriented utilitarian 
principle should guide resource allocation in conjunction 
with a prioritarian approach, which gives special 
consideration to socially and economically disadvantaged 
groups. The combination of prevailing ethical approaches 
and practical implications such as cost, safety, and resource 
allocation, can profoundly influence the decisions 
physicians make regarding PrEP recommendation and 
prescription.  
 
Although general knowledge about and support for PrEP 
have increased since the FDA approved Truvada and the 
CDC released the prescribing guidelines, knowledge of 
PrEP among providers has increased only slightly, and 
prescribing rates remain relatively low (Castel et al., 2015). 
The willingness of physicians to prescribe PrEP has 
significant implications for PrEP access; however, few 
studies have evaluated the attitudes of physicians towards 





The purpose of this literature review was to evaluate 
provider attitudes toward the ethics of use of PrEP for 
individuals at high risk for acquiring HIV infections. 
Provider concerns regarding the safety, efficacy, and cost-
effectiveness of the PrEP intervention were evaluated 
through the ethical framework of the utilitarian approach to 
ethical decision-making. All study protocols were reviewed 
and approved by the Georgia Southern University 
Institutional Review Board. 
 
 This literature review included peer-reviewed journal 
articles published between 2014 and 2017 reporting on 
physician attitudes towards prescribing PrEP. Only papers 
written in English were included. Data were collected by 
use of the PubMed and Cochrane search engines available 
through the Georgia Southern University Library GALILEO 
database system. To ensure that all articles that were eligible 
for review were captured, a broad initial search strategy was 
used for literature identification with the terms: “pre-
exposure prophylaxis” OR “PrEP,’ plus “HIV,” plus 
“physician hesitation,” and “Ethics” OR “Bioethics” OR 
“ethical issues” OR “normative” OR “ethical guidelines.” 
 
A second search was conducted to screen articles for 
keywords contained in titles and abstracts using the search 
terms: “PrEP allocation” OR “high risk” OR “PrEP plus 
efficacy” OR “PrEP plus HIV plus high risk” OR “PrEP 
plus resource plus allocation” OR “resource” AND “ethics” 
OR “ethical” OR “utilitarian” OR “utilitarianism” OR 
“physician” OR “provider” OR “safety” OR “effectiveness” 
OR “cost PLUS benefit” OR “debate” OR “dilemma.” Then 
a search was conducted through PubMed for the terms “pre-
exposure prophylaxis” AND “HIV” AND “physician” OR 
“provider” AND “ethics” AND “attitudes.” Finally, a search 
was conducted in PubMed using the terms “pre-exposure 
prophylaxis” OR “PrEP” AND “HIV” AND “physician” 
OR “provider” AND “ethics” OR “ethical” OR “bioethics.” 
Duplicate articles were eliminated. 
 
Three reviewers independently assessed the relevance of 
articles and discarded those not directly related to 
physician’s attitudes towards the ethics of the cost, safety, 
and resource allocation of PrEP. The first reviewer 
conducted the initial analysis. The second and third analyses 
were conducted, separately, by two additional reviewers. 
The criteria for inclusion were that each article must 
explicitly address considerations of PrEP treatment 
allocation, cost, safety, and/or efficacy, and must report on 
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healthcare provider perspectives. Articles that did not 
initially meet criteria were discussed by the reviewers, and 
only those articles that had full agreement were included. 
Twenty-one articles were ultimately included in this 




The literature review focused on provider attitudes 
regarding prescribing PrEP, including resource allocation, 
cost, and safety or effectiveness of the drug. Several of the 
researchers cited in the literature had formulated their own 
literature reviews or had conducted their own research on 
prescriber attitudes towards PrEP.  
 
Resource Allocation 
Some authors argued that resources allocated to the 
distribution of PrEP can negatively affect the availability of 
resources for HIV treatment. Sugarman & Mayer (2014) 
concluded that questions regarding resource allocation will 
not be easy to address if related factors, including cost, 
safety, and efficacy, remain in question. A notable 
consideration is that there are other effective HIV 
prevention methods, such as educational forums, 
counseling, and condom use. Sugarman & Mayer (2014) 
raised the point that funding for HIV prevention and 
treatment can be considered a draw on a larger, limited pool 
of general funding for health concerns ˗˗ a consideration that 
demands a more complex and broad assessment of PrEP 
funding allocation. A second aspect of resource allocation is 
the problem of determining which demographic ˗˗ not 
medical ˗˗ groups should be prioritized for PrEP, as 
insufficient resources exist to distribute the treatment 
regimen equally to all who may benefit from it. 
 
Cost 
Several studies focused on cost-effectiveness, investigating 
whether the benefits of preventing HIV through 
administering PrEP outweigh the costs of PrEP (Hankins et 
al., 2015; Hakre et al., 2016; Karris et al., 2014). Funding 
PrEP while other potentially more cost-effective HIV 
prevention interventions remain underfunded may have high 
opportunity costs, diverting resources from early initiation 
of anti-retroviral therapy or other prevention strategies 
(Hankins, Macklin, and Warren, 2015).  
 
Puro et al. (2013), through a focus group and literature 
review, developed a questionnaire that was administered to 
a convenience sample of Italian HIV specialists during 
educational courses in two regions and an online survey in 
February-May 2012. The participants were asked if they 
would allocate the costs of PrEP to the National Health 
System (NHS). Most respondents believed that NHS should 
sustain PrEP costs entirely, in all (28%) or selected (9%) 
cases (i.e., conception), or partially, based on patient’s 
income (29%) (Puro et al., 2013). Regarding financial 
sustainability, although it was deemed too expensive, most 
specialists advocated NHS support of PrEP costs to ensure 
equity of access, consistent with other studies in which 
healthcare providers recognized cost as a major barrier for 
patients and would like for public programs to pay for PrEP 
if patients cannot afford it (Puro et al., 2013). 
 
A systematic review of 13 studies found that key 
considerations in assessing cost-effectiveness of PrEP are 
cost, the epidemic context, individual adherence, PrEP 
program coverage, and prioritization strategy (Hankins, 
Macklin, and Warren, 2015). The researchers felt that PrEP 
could be a cost-effective addition to HIV prevention 
programs, particularly when those at highest risk of HIV 
exposure are prioritized (Hankins, Macklin, and Warren, 
2015). They also felt that paying for PrEP, when access to 
antiretroviral therapy is not universal, is an issue that 
requires reflection. To fulfill the public health need for 
PrEP, the researchers felt that PrEP introduction activities 
will enable policy-makers and program planners to answer 
the questions of who can benefit most from PrEP, how to 
provide it safely and efficiently, how to integrate PrEP into 
combination treatment and prevention programs, and what 
kind of health system support is needed to ensure 
implementation (Hankins, Macklin, & Warren, 2015).  
 
PCPs and infectious disease physicians in the US Air Force 
(USAF) participated in a cross-sectional survey examining 
knowledge, attitudes, and beliefs toward HIV and PrEP 
(Hakre et al., 2016). Barriers to PrEP utilization included 
concerns about costs, viral resistance, patient adherence, and 
side effects of medication. The low uptake of PrEP by 
USAF providers may be related to concerns reported in the 
survey and uncertainty about costs. 
 
A study by Castel et al. (2015) examined PrEP knowledge, 
experience, and likelihood of prescribing PrEP among HIV 
providers in Miami, FL, and Washington, DC. As stated in 
this report, 53% of the providers were concerned about the 
cost of the drug and reimbursement procedures (Castel et 
al., 2015). Latent class analysis was conducted to divide the 
providers into two groups: class one, who were identified as 
perceiving PrEP as less effective with substantial barriers; 
and class two, who perceived PrEP as being moderately 
effective with few barriers. Class two had a slightly higher 
probability of agreeing that cost might pose a substantial 
barrier (Castel et al., 2015). Both groups of providers also 
identified the risk for drug resistance and risk compensation 
as potential barriers to PrEP use—findings that were 
consistent with the results of other studies of potential 
physician providers of PrEP (Blumenthal et al., 2015; 
Caceres et al., 2015; Castel et al., 2016; Hakre et al., 2016; 
Hankins et al., 2015; Karris et al., 2014; Krakower et al., 
2014; Krakower et al., 2015; Krakower and Mayer, 2016; 
Puro et al., 2013; Smith et al., 2016).  
 
Safety/Effectiveness 
Prescribers were hesitant in prescribing PrEP because the 
effectiveness of the drug was considered equivocal 
(Blumenthal et al., 2015; Caceres et al., 2015; Castel et al., 
2016; Hakre et al., 2016; Hankins et al., 2015; Karris et al., 
2014; Krakower et al., 2014; Krakower et al., 2015; 
Krakower and Mayer, 2016; Puro et al., 2013; Smith et al., 
2016). PCPs reported lack of knowledge or training about 
PrEP as the main barrier in prescribing PrEP and in 
providing PrEP education to patients (Hakre et al., 2016). 
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A study by Blumenthal et al. (2015) explored prescriber 
attitudes about efficacy through a 35-question, self-
administered survey that was given to clinicians (N=233) 
who attended HIV-related conferences and meetings in New 
York, San Diego, and Los Angeles. The survey focused on 
knowledge and experience with PrEP and evaluated 
perceived advantages and disadvantages of PrEP being 
provided by clinicians who did and did not generally care 
for HIV-infected persons and high-risk, HIV-uninfected 
individuals (Blumenthal et al., 2015). The results showed 
that 40% of these providers were hesitant to prescribe PrEP 
because of patient resistance to the drug. Most (>80%) 
providers agreed that new studies showing efficacy, patient 
request, ease of patient obtaining PrEP, and 
recommendations from CDC would likely increase their use 
of PrEP (Blumenthal et al., 2015). Many of the reports 
indicated that patients would become resistant to the drug 
and that it would essentially be ineffective, which limited 
their willingness to prescribe PrEP (Blumenthal et al., 2015; 
Caceres et al., 2015; Castel et al., 2016; Hakre et al., 2016; 
Hankins et al., 2015; Karris et al., 2014; Krakower et al., 
2014; Krakower et al., 2015; Krakower and Mayer, 2016; 
Puro et al., 2013; Smith et al., 2016). 
 
A study by Karris et al. (2013) examined prescriber attitudes 
towards the safety of PrEP through a 10-question survey 
that was given to infectious disease specialists (N = 573) 
who belonged to The Emerging Infections Network of the 
Infectious Diseases Society of America. The survey 
inquired about the participants’ HIV practice, to whom they 
had provided or would provide PrEP, how they assessed 
eligibility, how they measured adherence, when PrEP would 
be discontinued, and what perceived barriers existed (Karris 
et al., 2014). When asked why physicians would not provide 
PrEP, 77% were worried about adherence and the risk for 
future resistance, 53% did not want to use potentially toxic 
drugs for healthy persons, and 53% felt there was 




Even though prescribers were aware of PrEP and its use, 
many were reluctant to prescribe it (Castel et al., 2015; 
Hakre et al., 2016 Krakower et al., 2015; Karris et al., 2015; 
Krakower and Mayer, 2012; Krakower and Mayer, 2016, 
Puro et al., 2013; Smith et al., 2016). For example, a survey 
of 184 clinicians working for a New England AIDS 
Educational and Resource Center was conducted to 
investigate prescribing practices (Krakower et al., 2015). 
The results indicated that clinicians were not readily 
prescribing PrEP. Of the respondents, 75% reported being 
aware of CDC PrEP guidelines, but only 19% had 
prescribed it. Having a higher percentage of patients 
infected with HIV was associated with a history of 
prescribing PrEP. This study was conducted at an institution 
specializing in HIV care, rather than in a primary care 
setting, a fact pointed out by survey respondents who 
believed that primary care and sexual health clinics may be 
more appropriate settings for prescription of PrEP. 
 
Several studies indicated that some prescribers supported 
PrEP but had not prescribed it because it was not relevant to 
their patient population. In a survey given to clinicians, 74% 
of respondents reported support for provision of PrEP, but 
only 9% had prescribed it. Of those surveyed, 34% reported 
that PrEP was not germane to their practice (Karris et al., 
2013). 
 
Puro, et al., (2013) assessed prescribers’ knowledge about 
PrEP and their willingness to prescribe it. HIV specialists 
(N=311) responded to a survey regarding attitudes toward 
PrEP. Of these, 69% rated their own familiarity with PrEP 
as being minimum or sufficient, and 70% reported that they 
would prescribe PrEP. These results support broader 
findings indicating a higher willingness to prescribe PrEP 
among HIV specialists (Puro et al., 2013). 
 
A survey was given to providers treating individuals with 
HIV to evaluate their willingness to prescribe PrEP (Castel 
et al., 2015). Of the participants, 50% reported that they 
were infectious disease specialists, and 75% reported that 
they were PCPs. However, only 17% of the HIV providers 
reported that they had prescribed PrEP, with slightly over 
half of the respondents reporting belief in the efficacy of 
PrEP. 
 
Several studies suggested that PrEP awareness and 
willingness to prescribe it are generally increasing (Castel et 
al., 2015; Hakre et al., 2016; Karris et al., 2015; Krakower 
et al., 2015; Krakower and Mayer, 2012; Krakower and 
Mayer, 2016; Puro et al., 2013; Smith et al., 2016). In one 
study conducted before and after the release of PrEP trial 
results, primary care clinicians reported that awareness of 
PrEP had increased from 24% in 2009 to 66% in 2015 
(Smith et al., 2015). In 2009, 1% of participants reported 
having prescribed PrEP; in 2015, 7% reported having 
prescribed PrEP. Willingness to prescribe PrEP was 
associated with experience in treating patients with 




The studies included in this review discussed the importance 
of resource allocation, safety, effectiveness, and cost 
benefits for prescribing PrEP. Realization of the societal 
value of PrEP will require identifying individuals who are 
most likely to benefit from it, monitoring for adverse 
effects, addressing costs, and training providers to prescribe 
PrEP responsibly (Krakower and Mayer, 2012). Many 
prescribers are hesitant in prescribing PrEP, mainly due to 
lack of knowledge and efficacy of the drug. Ensuring that 
PrEP fulfills its potential as part of a HIV prevention 
regimen requires establishing additional evidence, 
education, support services, and resources, as well as the 
regulatory framework and cost scenarios for access to PrEP 
(Hankins, Macklin, and Warren, 2015).  
 
The cost of PrEP has been cited as a provider concern, but 
the extent to which cost acts as a barrier remains unclear. 
Perception of cost as a barrier was associated with 
specialization in infectious diseases and/or HIV care. In a 
study of 573 infectious disease specialists, cost was cited as 
the main barrier and, in another study of 311 HIV 
specialists, was cited as the second largest barrier. Two 
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other studies (N = 403, N = 233), surveying a wider mix of 
providers, found that cost concerns were not among the 
highest perceived barriers (Blumenthal et al., 2015; Hakre et 
al., 2016; Karris et al., 2014; Puro et al., 2013).  
 
Due to the considerable expense of the drug, the issue of 
cost as a prohibitive factor in utilization of PrEP for patients 
is substantial. However, a utilitarian analysis of cost factors 
would aim to place these concerns in the broader context of 
healthcare accessibility, particularly for the high-risk 
populations that the drug regimen would benefit. The cost-
effectiveness of PrEP, from a utilitarian standpoint, would 
be determined by evaluating its effect on populations rather 
than individuals (Mandal, Ponnambath, & Parija, 2016). A 
limitation of the current body of research is that provider 
survey items regarding cost are likely to be interpreted at the 
individual level, imputing the cost to each patient. Further 
research investigating the barrier of price on high-risk 
populations most likely to derive the greatest benefits from 
the drug is warranted to clarify the relationship between 
individual and population-level ethical issues.  
 
Among providers, the effectiveness of PrEP and its potential 
for toxic side effects were oft-cited concerns. In a study of 
39 HIV care providers, participants discussed the issue of 
patient adherence to medication regimens as a barrier to 
PrEP efficacy (Krakower et al., 2014). Whether provider 
concerns over PrEP efficacy in all the studies reviewed were 
related to adherence, rather than efficacy of the drug 
regimen, is unclear; however, patient adherence was 
frequently cited as a reservation. 
  
A generally positive attitude toward the provision of PrEP 
was associated with provider knowledge and experience 
with PrEP, suggesting that provider education will be 
involved in shaping how PrEP is positioned as a preventive 
intervention for high-risk populations. Blumenthal et al. 
(2015) found that 80% of 233 providers reported that they 
would be more open to prescribing PrEP if more data on 
safety and efficacy become available. As levels of provider 
education increase, a demand for comparative data between 
established HIV prevention methods and PrEP intervention 
is likely to arise among professionals seeking a more 
complete understanding of whether the benefits of PrEP and 
other methods justify the costs.  
 
At present, PrEP provision is generally low (Karris et al., 
2014; Castel et al., 2015; Krakower & Mayer, 2016; Hakre 
et al., 2016). In keeping with reports that providers would be 
more open to prescribing PrEP after gaining greater 
certainty of its safety and efficacy, Smith et al. (2016) 
reported a slow increase in PrEP provision over a three-year 
span as PrEP awareness grew among the medical 
community. Still, as of 2015, only 7% of participants 
reported having prescribed PrEP, suggesting that some 
providers may be finding compelling reasons not to provide 
it. Inquiries should focus on how the oft-cited factors of 
adherence, toxicity, and the substantial cost of the drug 
regimen might be affecting provider perspectives on the 
potential for PrEP to reduce HIV transmission. 
 
Overall, few participants reviewed cited the issue of 
resource allocation among their chief concerns about PrEP. 
In the context of the provider-patient relationship, the distal, 
population-level impact of PrEP resource provision on 
availability of other HIV treatments may be a less salient 
consideration in provider decision-making. Further, resource 
allocation for healthcare varies considerably by country, 
suggesting that the question of how providers view the 
practice of drawing from limited funding for PrEP may vary 
according to culture-specific perceptions of resource 
availability and distribution (Davis, Stremikis, Schoen, & 
Squires, 2014). 
 
Considering disease burden, costing information, and 
efficacy, cost-effectiveness studies that illustrate the 
utilitarian principle at work can provide an initial indication 
of the potential effects of PrEP programs. In regard to 
administration of PrEP and ethics, cost-effectiveness 
becomes an issue. Unlike the context of private 
prescriptions, if PrEP becomes a state-recommended 
intervention, the question of cost versus benefit arises. Some 
of the questions posed by PrEP are not specific to HIV 
prophylaxis, but are standard public health considerations 
about resource allocation and striking a balance between 
individual benefits and public good. To increase access to 
PrEP, we need to understand the cost of PrEP and establish 
who is going to pay for it. Clinicians who prescribe PrEP 
have an ethical obligation to be aware of the current and 
emerging data concerning PrEP and the ethical issues 
associated with its use. 
 
Regarding ethics and PrEP, prescribers may have a moral 
issue in which they believe that prescribing PrEP will 
encourage risky behavior (Puro et al., 2013; Krakower et al., 
2015). There is also a concern that PrEP may lead to drug 
resistance, with resulting decreased efficacy of population-
level treatment; if this is the case, it may be argued that it is 
not ethical to prescribe it (Venter, Allais, and Richter, 
2014). The urgent-need principle states that medical needs 
of people give rise to moral claims to the health care 
resources necessary to meet those needs, that equally urgent 
needs give rise to equal moral claims, and that more urgent 
needs give rise to stronger moral claims (Brock et al., 2003). 
The urgent-need principle can be combined with the 
utilitarian principle in setting priorities for allocating PrEP, 
with the principle of equity giving priority to stigmatized 
and marginalized populations, such as men who have sex 
with men, sex workers, people who inject drugs, and young 
women and serodiscordant couples (Hankins, Macklin, and 
Warren, 2015). Introduction of PrEP will enable policy-
makers and program planners to answer the questions of 
who can benefit most from PrEP, how to provide it safely 
and efficiently, how to integrate PrEP into combination 
treatment and prevention programs, and what kind of health 
system support is needed to ensure implementation 
(Hankins, Macklin, and Warren, 2015).  
 
Conducting a comprehensive literature review, rather than a 
systematic review, allowed review and evaluation of a wide 
range of literature. This approach provided the flexibility to 
engage the broad knowledge base in the published literature; 
however, it has limitations. A comprehensive literature 
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review is subject to misinterpretation of data. Additionally, 
although broad search terms were used, some literature may 
have been overlooked. PrEP is relatively new as a 
prevention approach, having been approved by the FDA in 
2012. Most of the studies cited in this review were 
published between 2014 and 2016. Therefore, even the most 
recent studies published on this topic may not reflect the 
most up-to-date research and information pertaining to 
PrEP.  
 
The innovative use of Truvada for the prevention of HIV 
infection represents a new development in the fight against 
the spread of HIV. If PrEP can be shown to have a positive 
net benefit to high-risk populations and these communities, 
public health professionals can lead the call for policies and 
programs that make the drug regimen more accessible to 
vulnerable populations. Current data suggest that decision-
making at the provider level is stalled by the lack of data 
pertaining to PrEP safety and efficacy. Further, providers 
are hesitant to support the prevention method because it 
simply is not affordable for many patients. Further research 
into the safety and efficacy of PrEP is needed in order to 
build a case for the public benefit of devoting resources to 
the allocation of PrEP that would withstand a utilitarian 
analysis. If data demonstrate that spending on PrEP is likely 
to reduce HIV transmission rates in high-risk communities, 
advocates can push for policies that would help lower the 
cost of PrEP for patients, and efforts to educate providers on 
the benefits of PrEP will meet with greater success.  
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